1What does pharmacokinetics describe?
Drug movement through the body: absorption, distribution, metabolism, and excretion (ADME)
2What does pharmacodynamics describe?
The biochemical and physiologic effects of a drug on the body
3Why must ICU drug dosing be reassessed frequently?
PK variables can change rapidly and with high frequency during critical illness
4What is the bioavailability of an IV medication?
100%; the entire dose reaches systemic circulation
5Does IV administration guarantee adequate drug concentrations in tissues?
No. Hydrophilic drugs may penetrate poorly into meninges, pulmonary tissue, and bone
6What injury can occur after norepinephrine extravasation?
Local vasoconstriction and tissue necrosis
7Can enteral drug exposure increase as well as decrease in ICU patients?
Yes. Different medications can have increased or decreased bioavailability
8Which non-IV routes bypass hepatic first-pass metabolism?
Subcutaneous and intramuscular administration
9Why can subcutaneous or IM absorption change during shock?
Changes in perfusion alter delivery of drug into the blood
10What is the primary PK goal of inhaled drug administration?
High pulmonary drug concentrations with reduced systemic exposure
11What inhaled particle size best reaches all regions of the lungs?
1–5 micrometers
12Are inhaled antibiotic efficacy data firmly established in ICU patients?
No. The chapter describes efficacy of this route as not well established
13Why administer antibiotics intraventricularly for resistant meningitis?
To increase local drug concentrations and reduce systemic concentrations
14What does bioavailability (F) measure?
The percentage of a dose that reaches the systemic circulation
15How may shock affect gastrointestinal drug absorption?
Splanchnic hypoperfusion is thought to decrease absorption; direct studies are lacking
16What bedside test has been investigated as a surrogate for GI drug absorption?
An oral acetaminophen test with subsequent serum concentrations
17What effect may reduced skin and muscle perfusion have on SC or IM drugs?
It is thought to reduce absorption from these sites
18Does intestinal atrophy consistently increase or decrease drug absorption?
Unknown; passive diffusion may increase while active transport may decrease
19How common can GI dysmotility be in critically ill patients?
Reported incidence as high as 60%
20How does delayed gastric emptying usually change acetaminophen absorption?
Delayed absorption and a reduced peak concentration
21Name two common treatments for ICU GI dysmotility.
Metoclopramide and erythromycin
22Is the effect of prokinetics on enteral drug absorption established in ICU patients?
No; it remains unclear
23What is the general effect of intestinal P-glycoprotein on substrate absorption?
It reduces absorption of drug substrates
24Which fluoroquinolone has reduced bioavailability with enteral nutrition (except its oral suspension)?
Ciprofloxacin
25Which three commonly used drugs have reported reduced absorption with enteral nutrition?
Levothyroxine, phenytoin, and warfarin
26What enteral-feeding hold interval is suggested for interacting drugs?
1–2 hours before and after drug administration; use the minimum interruption needed
27Why should prolonged enteral-feed interruptions be avoided?
They may reduce nutrition support and increase administration workload and errors
28What effect does increased gastric pH have on ketoconazole/itraconazole absorption?
Decreased absorption
29Which cardiac medication has increased absorption with acid suppression in the chapter?
Digoxin (also nifedipine)
30Why can a jejunostomy tube reduce oral iron absorption?
Iron is dissolved in the stomach and absorbed in the duodenum
31Is tolerance of enteral feeding a reliable marker of drug absorption?
No. The chapter describes it as not an ideal marker
32What does volume of distribution (Vd) relate?
The amount of drug in the body to its serum concentration
33For an IV dose, what is the relationship between initial serum concentration and Vd?
$C = Dose/V_d$
34For the same IV dose, what happens to initial serum concentration when Vd increases?
It decreases
35Which drug type generally has increased Vd after large-volume resuscitation?
Hydrophilic drugs
36How is Vd of lipophilic drugs generally affected by increased interstitial fluid?
It is often unchanged
37Name three conditions that may increase interstitial fluid and hydrophilic-drug Vd.
Sepsis, ARDS, and AKI (also burns, HF, cirrhosis, surgery)
38How did septic shock affect piperacillin subcutaneous tissue exposure in a cited study?
Reduced tissue concentrations versus healthy volunteers
39Which plasma protein usually binds acidic drugs?
Albumin
40Which plasma protein usually binds basic drugs?
Alpha-1 acid glycoprotein (AAG)
41How does albumin generally change during physiologic stress?
It decreases (negative acute-phase reactant)
42How does AAG generally change during physiologic stress?
It increases (positive acute-phase reactant)
43What happens to the unbound fraction of an albumin-bound drug in hypoalbuminemia?
The unbound fraction (fu) increases
44How can hypoalbuminemia affect Vd of an albumin-bound drug?
The Vd can increase as plasma free fraction rises
45How can elevated AAG affect the Vd of an AAG-bound drug?
Increased binding decreases fu and Vd
46What relationship does the chapter give for protein binding and Vd?
$V_d=(f_u/f_{ut})\times V_t+V_p$
47Which antiepileptic had elevated free concentrations associated with hypoalbuminemia?
Valproate
48Which form of a drug penetrates cell membranes more easily?
The nonionized form
49Theoretically, how does acidemia affect Vd of a weak acid?
Increases Vd because more drug is nonionized; human evidence is lacking
50Theoretically, how does acidemia affect Vd of a weak base?
Decreases Vd because more drug is ionized; human evidence is lacking
51What is the most commonly reported ECMO-related PK change?
An increase in volume of distribution
52Which two ECMO circuit components may sequester drugs?
Circuit tubing and membrane oxygenator
53How can ECMO priming fluid affect drug distribution?
Its volume, type, and pH may increase drug Vd
54How might drug requirements change as an ECMO circuit ages?
Binding sites may saturate, allowing requirements to return toward pre-ECMO doses
55What does a higher logP indicate regarding ECMO circuit sequestration risk?
Greater lipophilicity and potentially higher sequestration risk
56Which ICU drug pair has demonstrated ECMO circuit loss in ex vivo studies?
Fentanyl and midazolam
57What monitoring did a pilot ECMO study recommend for β-lactams and aminoglycosides?
Therapeutic drug monitoring because PK target attainment was variable
58What is the predominant organ for drug metabolism?
The liver
59What change in insulin disposition contributes to hypoglycemia during AKI?
Decreased renal metabolism and lower insulin requirements
60What three factors determine hepatic drug metabolism?
Hepatic blood flow, protein binding, and intrinsic enzyme activity
61What is the basic hepatic clearance equation?
$CL_H = Q \times E$ (Q = hepatic blood flow, E = extraction ratio)
62What equation relates extraction ratio to intrinsic clearance and hepatic flow?
$E=(f_u\times CL_{int})/(Q+f_u\times CL_{int})$
63How is hepatic extraction ratio (E) classified as high?
Greater than 0.7
64How is hepatic extraction ratio (E) classified as intermediate?
0.3–0.7
65How is hepatic extraction ratio (E) classified as low?
Less than 0.3
66Which variable primarily limits clearance of high-extraction hepatic drugs?
Hepatic blood flow (Q)
67What simplified clearance equation applies to high-extraction hepatic drugs?
$CL_H = Q$
68Which two drugs in the chapter are high-extraction and albumin-bound?
Morphine and propofol (other examples are in the chapter table)
69Which high-extraction drug in the chapter binds AAG?
Lidocaine
70What happens to total and unbound Css of a high-extraction drug when hepatic flow increases?
Both decrease
71What happens to total and unbound Css of a high-extraction drug when hepatic flow decreases?
Both increase
72For a high-extraction drug, what happens to total Css if protein-free fraction increases?
No change in total Css
73For a high-extraction drug, what happens to unbound Css if protein-free fraction increases?
Unbound Css increases
74Which hemodynamic state may increase hepatic clearance of high-extraction drugs?
Hyperdynamic sepsis with increased hepatic perfusion (theoretical in humans)
75What shock state may increase exposure to high-extraction drugs?
Low-output shock with reduced hepatic blood flow
76Why may positive-pressure ventilation reduce hepatic clearance?
Increased intrathoracic pressure may reduce venous return and cardiac output
77Which two albumin-bound drugs in the chapter are LOW-extraction?
Phenytoin and warfarin
78Which albumin-bound sedative in the chapter has an INTERMEDIATE extraction ratio?
Midazolam
79Which variable primarily limits clearance of low-extraction hepatic drugs?
Intrinsic enzyme activity, together with unbound fraction
80What simplified clearance equation applies to low-extraction hepatic drugs?
$CL_H = f_u \times CL_{int}$
81Does altered hepatic blood flow directly affect Css of a low-extraction drug?
No; both total and unbound Css are unchanged in the model
82What happens to total and unbound Css of a low-extraction drug when intrinsic clearance decreases?
Both increase
83What happens to total Css of a low-extraction drug if free fraction increases?
Decreases
84What happens to unbound Css of a low-extraction drug if free fraction increases?
No change in the model
85How do CYP inhibitors usually affect concentrations of coadministered substrates?
They increase substrate concentrations
86How do CYP inducers usually affect concentrations of coadministered substrates?
They decrease substrate concentrations
87Which inflammatory mediators suppress CYP expression and activity?
IL-1, IL-6, and TNF-alpha
88What effect can early sepsis have on intrinsic hepatic clearance?
Inflammatory cytokines may decrease CYP activity
89What effect did mild hypothermia have on phenytoin metabolism?
Reduced metabolism with increased concentrations; protein binding was unchanged
90What effect has worsening AKI been associated with for midazolam concentrations?
Increasing concentrations, possibly from impaired CYP3A activity
91What determines clearance of intermediate-extraction drugs?
Hepatic blood flow, intrinsic clearance, and unbound fraction
92During early traumatic brain injury, how may phenytoin hepatic clearance change?
It can increase during the first 7–14 days
93Which phase II substrate had increased clearance in TBI and thermal injury?
Lorazepam
94Which three processes govern urinary drug excretion?
Filtration, secretion, and reabsorption
95What is augmented renal clearance (ARC)?
Increased renal drug elimination associated with increased renal blood flow/filtration
96Which major conditions are associated with ARC in ICU patients?
Surgery, trauma, burns, and early sepsis
97Name three common patient characteristics associated with ARC.
Younger age, trauma, and low serum creatinine
98What may happen to renal elimination during the hyperdynamic burn phase?
Increased excretion of drugs such as vancomycin and aminoglycosides
99In which direction can renal clearance change as early sepsis progresses to AKI?
From increased clearance to decreased clearance
100What is the major dosing risk when renal excretion falls during AKI?
Drug accumulation and toxicity
101Do the KDIGO AKI staging guidelines provide specific drug-dosing instructions?
No
102Why might FDA renal-dose recommendations be imperfect for acute ICU kidney injury?
They are often based on chronic kidney disease populations
103What should be monitored when individualizing drug doses during AKI?
Response, toxicity, and drug levels (when available), with reassessment
104Which three equations for estimating kidney function does the chapter discuss?
Cockcroft–Gault, MDRD, and CKD-EPI
105What is the Cockcroft–Gault equation for creatinine clearance?
$CrCl = [(140-age)\times weight]/(72\times SCr)$; multiply by 0.85 for females
106What units does the Cockcroft–Gault equation use for weight and SCr?
Kilograms and mg/dL, respectively
107Which kidney-function estimate is emphasized over MDRD by the National Kidney Foundation?
CKD-EPI
108Which factors affect removal of a drug by intermittent hemodialysis?
Molecular size, Vd, protein binding, and filter membrane
109Can intermittent HD remove all medications to the same degree?
No. Drug removal depends on drug and dialyzer characteristics
110What is the most important CKRT parameter for drug removal in this chapter?
Effluent flow rate (Qeff)
111How does increasing CKRT effluent flow affect solute clearance?
It increases solute clearance
112In the chapter’s CKRT dose equation, what does SC stand for?
Sieving coefficient
113What CKRT dose adjustment equation is presented in the chapter?
$Dose = Dose_n \times [CL_{nonrenal} + Q_{eff}\times SC]/CL_{norm}$
114Which neuromuscular blockers had prolonged half-lives during biliary obstruction or cholestasis?
Pancuronium and vecuronium
115What are the three major antibiotic PK/PD efficacy indexes?
Time above MIC, peak/MIC, and AUC/MIC
116Which PK/PD index predicts β-lactam effectiveness?
Free-drug time above MIC (fT>MIC)
117What ideal fT>MIC percentage is described for β-lactams?
100% (studied targets vary)
118What fT>MIC cutoff is cited for carbapenem efficacy?
About 40%
119What fT>MIC cutoff is cited for penicillin efficacy?
About 50%
120What fT>MIC cutoff range is cited for cephalosporin efficacy?
About 50–75%
121Why may prolonged or continuous β-lactam infusions improve PD target attainment?
They increase time above MIC
122Have controlled trials consistently shown benefits from prolonged β-lactam infusion?
No. Prospective trial results are mixed
123Which PK/PD index best characterizes aminoglycoside killing?
Peak concentration/MIC (Cmax/MIC)
124What aminoglycoside peak/MIC ratio correlated with about 90% clinical response?
8–10
125Why is extended-interval aminoglycoside dosing pharmacodynamically attractive?
It takes advantage of high peak concentrations
126Which PK/PD index best predicts vancomycin efficacy?
AUC/MIC
127What vancomycin AUC target range is recommended for efficacy and safety?
400–600 (AUC/MIC framework)
128What vancomycin loading-dose range is recommended in the chapter?
20–35 mg/kg based on actual body weight
129When may continuous-infusion vancomycin be considered?
When conventional dosing cannot achieve target AUC
130What IV access concern accompanies continuous-infusion vancomycin?
Y-site incompatibilities with several common ICU medications
131What fluoroquinolone peak/MIC ratio is cited in the chapter?
10 or greater
132What ciprofloxacin AUC/MIC exposure was associated with clinical cure in a cited respiratory infection study?
125 for 24-hour AUC/MIC
133Why are individualized fluoroquinolone PK/PD targets difficult to verify?
Routine serum drug concentrations are not available
134What monitoring test is commonly used for the PD response to UFH infusion?
Activated partial thromboplastin time (aPTT)
135How did septic shock affect dobutamine response in a cited study?
Reduced response compared with nonseptic patients and healthy volunteers
136What are the two primary goals of therapeutic drug monitoring (TDM)?
Maximize efficacy and reduce toxicity
137Which drugs are especially appropriate for TDM?
Drugs with a narrow therapeutic index
138What is a practical barrier to widespread antimicrobial TDM?
Limited assays and timely results
139What total phenytoin trough range is shown in the chapter?
10–20 mg/L
140What unbound phenytoin trough range is shown?
1–2.5 mcg/mL
141What total valproate trough range is shown?
50–100 mcg/mL
142What caveat does the book give for the unbound valproate range?
Its optimal range remains undetermined
143What carbamazepine trough range is shown?
4–12 mg/L
144What phenobarbital trough range is shown?
10–40 mg/L
145What digoxin trough sampling interval is shown?
8–24 hours after the dose
146What vancomycin exposure range is shown in the TDM table?
AUC 400–600 mg·hour/L
147What peak is listed for traditional gentamicin/tobramycin dosing?
8–10 mg/L
148What trough is listed for traditional gentamicin/tobramycin dosing?
Less than 2 mg/L
149What is the recommended trough goal for extended-interval aminoglycoside doses in the table?
Undetectable
150How is the first-order elimination rate constant (ke) calculated from two concentrations?
$k_e = ln(C_1/C_2)/\Delta t$
151What formula relates drug half-life to elimination rate constant?
$t_{1/2}=0.693/k_e$
152How does the book back-extrapolate a postinfusion peak to the end of infusion?
$C_{max} = C_1 \times e^{k_e t}$
153How does the book extrapolate a trough forward to the next dose?
$C_{min} = C_2 \times e^{-k_e t}$
154What formula is given for a new dosing interval from desired peak and trough?
$\tau=\ln(C_{max,desired}/C_{min,desired})/k_e+t_{inf}$
155What assumption is a drawback of using trough-based TDM alone?
That a PK measurement (e.g., trough) correlates with PD exposure (e.g., AUC/MIC)
156Why might population-PK software misdose an ICU patient?
Models based on non-critically ill patients may misrepresent ICU PK
157Which additional antimicrobial classes/drugs are recommended for TDM in a cited position paper?
β-lactams, linezolid, and voriconazole (in addition to aminoglycosides/vancomycin)
158What do once-daily aminoglycoside dosing nomograms commonly determine?
The dosing interval, using sampling time and drug concentration
159Why must Hartford-type nomograms be applied cautiously in ICU patients?
They were not developed in critically ill patients and may miss altered PK
160What population-specific risk applies to insulin infusion protocols in AKI?
Higher hypoglycemia risk if protocols were developed without kidney impairment
161High-extraction drug: ↑ hepatic blood flow. What happens to total and unbound Css?

Both decrease
162Low-extraction drug: ↑ free fraction. What happens to total and unbound Css?

Total decreases; unbound unchanged
163Phenytoin: recall the TOTAL and UNBOUND trough ranges.

Total 10–20 mg/L; unbound 1–2.5 mcg/mL
164Carbamazepine: recall total and unbound trough ranges.

Total 4–12 mg/L; unbound 0.5–4 mcg/mL
165Vancomycin: recall the target AUC range.

AUC 400–600 mg·hour/L
166Gentamicin: recall the traditional peak and trough ranges.

Peak 8–10 mg/L; trough <2 mg/L